Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for relapsed or refractory multiple myeloma, a type of blood cancer that has returned or is not responding to previous treatments. The study will explore the use of a new medication called BGB-11417, both on its own and in combination with other treatments. These combinations include dexamethasone, a medication that reduces inflammation, and other drugs such as carfilzomib, daratumumab, and pomalidomide. The purpose of the study is to determine the safety and effectiveness of these treatments.

The study will be conducted in two parts. In the first part, different doses of BGB-11417 will be tested to find the most suitable dose when used with the other medications. In the second part, the study will expand to include more patients to further evaluate the safety and effectiveness of BGB-11417 alone and in combination with the other drugs. Patients will receive these treatments through various methods, such as oral tablets, injections, or infusions, depending on the specific medication.

Throughout the study, researchers will monitor patients for any side effects and assess how well the treatments are working. The goal is to find the best treatment options for patients with relapsed or refractory multiple myeloma, particularly those with a specific genetic feature known as t(11;14). This study aims to provide new insights into managing this challenging condition and improving patient outcomes.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including a diagnosis of multiple myeloma and previous treatment history.

    A fresh bone marrow sample is collected for testing specific genetic markers.

  2. Step 2

    Part 1: dose escalation

    The initial phase involves determining the safe dosage levels of the new medication, BGB-11417, in combination with other drugs.

    Medications include dexamethasone (oral and IV), carfilzomib (intravenous infusion), daratumumab (subcutaneous use), and pomalidomide (oral).

    The focus is on assessing safety and identifying any side effects.

  3. Step 3

    Part 2: cohort expansion

    This phase evaluates the effectiveness of BGB-11417 alone and in combination with other medications at the recommended doses.

    The goal is to measure the response rate and monitor any adverse effects.

    The treatment combinations include BGB-11417 with dexamethasone, and with dexamethasone plus carfilzomib.

  4. Step 4

    Monitoring and follow-up

    Throughout the trial, regular monitoring is conducted to assess the treatment's impact on the condition.

    The study aims to track the time to response, duration of response, and overall survival rates.

  5. Step 5

    Completion of the trial

    The trial is expected to conclude by March 2027.

    Final assessments will determine the overall effectiveness and safety of the treatment combinations.

Who can join the trial?

18 criteria

  • Must have an ECOG performance status of 0 to 2. This is a scale that measures how well you can perform daily activities.
  • Must have a confirmed diagnosis of multiple myeloma.
  • Must have a measurable disease, which means one of the following:
    • M-spike in blood is 500 mg/dL or more, or
    • Urine protein M-spike is 200 mg/day or more, or
    • Serum free light chains are 10 mg/dL or more, with an abnormal kappa to lambda ratio.
    • Must have relapsed or progressive multiple myeloma after any treatment or be unresponsive to the most recent treatment.
      • Relapsed means the disease has returned after treatment.
      • Refractory means the disease does not respond to treatment or worsens within 60 days of the last treatment.
      • For Part 1, must have relapsed or progressive disease and have had 3 or more previous treatments, including a proteasome inhibitor, an IMiD (a type of drug), and an anti-CD38 monoclonal antibody.
      • For Part 2 (Cohorts 1 and 2), must have relapsed or progressive disease and have had 3 or more previous treatments, including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody.
      • For Part 2 (Cohorts 3, 4, and 5):
        • Must have relapsed or progressive disease and have had 1 or more previous treatments.
        • Must have been treated with a combination therapy that includes an anti-CD38 monoclonal antibody.
        • Previous treatment with carfilzomib is allowed, but you must not be considered resistant to it and must not have received it in the past 6 months.
        • Must test positive for t(11;14) using a specific test in a central laboratory. This involves collecting a fresh bone marrow sample during screening.
        • Must have adequate organ function, which includes:
          • Hemoglobin level of 8.0 g/dL or more within 7 days before the first dose, without the need for growth factor support or transfusions.
          • Platelet count of 75,000/μL or more within 7 days before the first dose, without the need for growth factor support or transfusions.
          • Absolute neutrophil count (ANC) of 1000/mm3 or more within 7 days before the first dose.
          • ALT and AST levels that are 3 times or less the upper limit of normal, and total bilirubin that is 2 times or less the upper limit of normal.
          • Serum creatinine level that is 1.5 times or less the upper limit of normal, or a creatinine clearance of 45 mL/min/1.73 m2 or more.

Who cannot join the trial?

10 criteria

  • Patients who have a different type of cancer other than relapsed or refractory multiple myeloma cannot participate. This means the study is only for those whose multiple myeloma has returned or did not respond to treatment.
  • Patients who are not within the specified age range for the study cannot participate. The study is designed for certain age groups only.
  • Patients who are not able to follow the study procedures or take the study medications as required cannot participate.
  • Patients who have certain other health conditions that might interfere with the study or make it unsafe for them to participate cannot join the study.
  • Patients who are pregnant or breastfeeding cannot participate, as the study may involve risks to the baby.
  • Patients who are currently participating in another clinical trial cannot join this study, to avoid interference with results.
  • Patients who have had a recent major surgery or are recovering from a major illness may not be eligible to participate.
  • Patients who have a history of allergic reactions to the study medications or similar drugs cannot participate.
  • Patients who have certain infections or diseases that could affect the study results or their safety cannot join the study.
  • Patients who have a history of substance abuse or other conditions that might affect their ability to follow the study requirements cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Sonrotoclax

    is an investigational medication being studied for its potential to treat patients with relapsed or refractory multiple myeloma, particularly those with a specific genetic marker known as t(11;14). It is being tested both as a standalone treatment and in combination with other medications to determine its safety and effectiveness.

  • Dexamethasone

    is a type of corticosteroid medication that is used to reduce inflammation and suppress the immune system. In this trial, it is combined with other treatments to help manage multiple myeloma and enhance the effects of other medications.

  • Carfilzomib

    is a medication used to treat multiple myeloma by inhibiting the proteasome, a protein complex that breaks down proteins in cells. By blocking this process, carfilzomib can help kill cancer cells. It is being tested in combination with dexamethasone and sonrotoclax to assess its effectiveness in this trial.

  • Daratumumab

    is a monoclonal antibody that targets a specific protein on the surface of multiple myeloma cells, helping the immune system to identify and destroy these cancer cells. In this study, it is used in combination with dexamethasone and sonrotoclax to evaluate its potential benefits for patients.

  • Pomalidomide

    is a medication that modifies the immune system and has anti-cancer effects. It is used in combination with dexamethasone and sonrotoclax in this trial to explore its role in treating multiple myeloma, particularly in patients who have not responded to other treatments.

What is already known about the treatment

Sonrotoclax – Sonrotoclax is an investigational medication currently being studied in clinical trials for its potential use in treating relapsed or refractory multiple myeloma, particularly in patients with a specific genetic marker known as t(11;14). It is administered orally and is being evaluated both as a standalone treatment and in combination with other drugs like dexamethasone, carfilzomib, daratumumab, and pomalidomide. The main therapeutic indication is to manage multiple myeloma that has not responded to previous treatments. Sonrotoclax works by inhibiting proteins that prevent cancer cell death, thereby promoting the destruction of these cells. It is classified as a BCL-2 inhibitor, a type of drug that targets specific proteins involved in cell survival.

Investigated diseases

Relapsed or Refractory Multiple Myeloma – This is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In relapsed or refractory cases, the disease has returned after treatment or does not respond to standard therapies. It typically progresses by causing an overproduction of abnormal plasma cells, leading to bone damage, kidney issues, and weakened immune function. Patients may experience symptoms such as bone pain, fatigue, and frequent infections. The disease can be challenging to manage due to its resistance to treatment and tendency to recur.
Trial detailsLast updated 4 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-507751-30-00Protocol codeBGB-11417-105Estimated enrolment211 patientsSponsorBeOne Medicines AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.